Citations

Institution: Mayo Clinic Clear

Showing 10 of 108094 citations.

Gastro-Entero-Colic Fistula After Successful EUS Guided Gastroenterostomy
Ladd, Antonio Mendoza , Ladna, Michel, Pecha, Luke, Sharzehi, Kaveh , Bhardwaj, Meera., Vargas, Jorge, Gutierrez, Olaya I. Brewer , Schlag, Christoph , Hindryckx, Pieter , Hucl, Tomáš , Sethi, Amrita , Masaryk, Viliam , Khara, Harshit S. , Mendoza Ladd, Antonio , Pérez‐Cuadrado‐Robles, Enrique , Han, Samuel , Vargas, Jorge, Inamdar, Sumant , Pham, Khanh Do-Cong

Journal of Clinical Gastroenterology | July 21, 2025 | Volume: 60 | Issue: 6 | Pages: 543-548

10.1097/mcg.0000000000002178 | PMID 40689823 Get It

Background: EUS-guided gastroenterostomy (EUS-GE) is an effective option for the management of gastric outlet obstruction (GOO). Due to the poor prognosis of patients undergoing it, data on its long-term adverse events (AE) is scarce. Herein, we describe a cohort of patients with gastro-entero-colic fistula (GECF) as a late AE of previously successful EUS-GE. Methods: Patients who developed a GECF after EUS-GE from 10 high-volume centers were analyzed. Information collected included demographic characteristics, indications, clinical and technical success rates, stent type and size, fistula characteristics, management, and outcomes. Results: Sixteen cases were identified. The mean interval from index EUS-GE to the diagnosis of GECF was 4 to 8 weeks. The most common cause of GOO was pancreatic adenocarcinoma (PDAC). The transverse colon was the most common site for the GECF (14 patients). A 20×10 mm lumen apposing metal stent (LAMS) was utilized in 10 patients. Endoscopic management with a variety of modalities was successful in 13 cases. Follow-up interval after endoscopic management of the fistula averaged 2 to 4 weeks. At the time of the manuscript elaboration, 10 patients had died, 5 were alive, and 1 was lost to follow-up. Conclusions: This is the first description of a cohort of patients with GECF after EUS-GE. The exact mechanisms leading to GECF in these cases are unknown. Possible explanations include inadvertent colon puncture during the index procedure and/or entrapment of mesocolon. More data is needed to further characterize this AE.
Estimated Out-of-Pocket Costs for Patients With Common Cancers and Private Insurance
Rose, Liam , Nambiar, Anjali, Pohl, Alexa L., Ruddy, Kathryn J. , Arnow, Katherine , Patel, Manali I. , Morris, Arden M. , Rajasekar, Ganesh

JAMA Network Open | July 21, 2025 | Volume: 8 | Issue: 7 | Pages: e2521575

10.1001/jamanetworkopen.2025.21575 | PMID 40690219 Get It

ImportanceCancer imposes a substantial economic burden on patients that may be worse in patients with higher-stage disease due to the need for more therapy.ObjectiveTo investigate the out-of-pocket costs (OOPCs) attributable to the initial treatment of common cancers among privately insured individuals diagnosed at different stages.Design, Setting, and ParticipantsThis retrospective cohort study used administrative claims data of a large national insurer in the US linked to the Surveillance, Epidemiology, and End Results (SEER) cancer registry to compare OOPCs of individuals diagnosed with breast, colorectal, and lung cancer at different stages with OOPCs of similar individuals without cancer using difference-in-differences methods. Individuals living in the US between 2008 and 2022, aged younger than 65 years, insured through a large national private health insurer, and with 6 or more months of continuous enrollment were included. Data were analyzed from June 2024 through February 2025.ExposureThe presence or absence of an incident cancer diagnosis and disease stage from the SEER registry diagnosed from 2008 to 2019.Main Outcomes and MeasuresThe primary outcome was OOPCs among individuals with breast, colorectal, and lung cancer diagnosed at different disease stages compared with those with no cancer diagnosis.ResultsThe cohort consisted of 46 158 patients (mean [SD] age at diagnosis, 46 [12] years; 30 733 female [66.6%]; 2543 Asian [5.5%], 4114 Black [8.9%], 3590 Hispanic [7.8%], and 31 099 White [67.4%]), including 19 656 patients with cancer and 26 502 patients without cancer in the control group. Among patients with cancer, 14 581 patients had breast cancer, 2842 patients had colorectal cancer, and 2233 patients had lung cancer. An incident cancer diagnosis was associated with a mean increase in OOPCs of $592.53 per month (95% CI, $528.01-$627.04 per month) for the 6 months after the diagnosis. Cost monotonically increased with stage at diagnosis (mean OOPC increase range, $462.01 per month [95% CI, $417.92-$506.11 per month] for stage 0 to $719.97 per month [95% CI, $626.11-$813.83 per month] for stage 4).Conclusions and RelevanceIn this study of individuals with private insurance, patients faced high OOPCs after an incident diagnosis of cancer, with patients with more advanced cancer having the highest OOPCs. Further research is needed to determine the clinical and financial effects of increased OOPCs for patients with cancer.
Malnutrition and Opioid Use Disorder Are Associated With Higher 30-day Readmission Rates in Patients Admitted for Ulcerative Colitis
Odah, Tarek , Palacios, Pedro , Fluxá, Daniela , Kinnucan, Jami , Picco, Michael F., Sulbaran, Marianny, Sulbaran, Marianny , Hashash, Jana G. , Farraye, Francis A.

Journal of Clinical Gastroenterology | July 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mcg.0000000000002189 | PMID 40689835 Get It

Background and Goals: Ulcerative colitis (UC) readmissions to the hospital pose a burden to patients and health care systems. Preventing readmissions is important for the quality of care and quality of life of patients with UC. We aimed to identify the incidence of 30 and 90-day readmissions and its predictors in patients with UC. Study: Retrospective review of the 2018 National Readmission Database (NRD) of adult patients readmitted after an index admission (IA) of UC. ICD-10CM/PCS codes were used to identify patients with UC, other comorbidities, and procedures. We identified the most common causes for readmission and independent risk factors for readmission were identified using Cox regression analysis. Results: The 30 and 90-day readmission rates for UC in 2018 were 16.6% and 28.3%. In-hospital mortality and mean length of stay were higher in patients readmitted within both 30 and 90 days. Independent predictors of 30-day readmission were higher Charlson Comorbidity Index (CCI), undergoing ileostomy, increasing length of stay, malnutrition and opioid use disorder at IA. In the 90-day readmission cohort, independent predictors were CCI score of 2 or ≥3, developing shock, admission to large bed size hospitals, undergoing colectomy, increasing length of stay and opioid use disorder at IA. The number one readmission cause at 30 and 90 days was sepsis of unspecified organism. Conclusion: Readmission is associated with higher mortality and is associated with risk factors such as malnutrition, undergoing ileostomy during IA and opioid use disorder. Readmissions in UC continue to pose a high burden to patients and our health care system.
Ovarian Cancer
Caruso, Giuseppe , Weroha, S. John, Cliby, William A. , Cliby, William, Weroha, S. John

JAMA | July 21, 2025 | Volume: 334 | Issue: 14 | Pages: 1278

10.1001/jama.2025.9495 | PMID 40690248 Get It

Importance Ovarian cancer is the eighth most common cause of cancer and cancer death in women worldwide. In 2022, ovarian cancer was diagnosed in approximately 324 398 individuals, and 206 839 died of ovarian cancer worldwide. In 2025, it is estimated that 20 890 US women will be diagnosed with ovarian cancer and 12 730 patients will die of ovarian cancer. Observations Approximately 90% of ovarian cancers are epithelial malignancies, of which 70% to 80% are high-grade serous ovarian cancers. Less common epithelial subtypes include endometrioid, clear cell, low-grade serous, mucinous, and carcinosarcoma. The median age at diagnosis of ovarian cancer is 63 years. Risk factors include older age, family history of breast or ovarian cancer, endometriosis, and nulliparity. Hereditary factors are associated with 25% of cases, predominantly linked to BRCA1 / 2 gene variants. At diagnosis, approximately 95% of patients experience nonspecific symptoms, such as abdominal pain, bloating, and urinary urgency and frequency, and about 80% have advanced-stage disease (stage III-IV), including extrapelvic disease, ascites, and abdominal masses. Diagnostic and staging evaluation includes pelvic ultrasound; computed tomography of the chest, abdomen, and pelvis; and serum tumor markers such as carbohydrate antigen 125, carbohydrate antigen 19-9, and carcinoembryonic antigen. First-line treatment for early-stage ovarian cancer, defined as limited to the ovary or fallopian tube (stage I) or confined to the pelvis (stage II), is surgery (hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy), followed by adjuvant chemotherapy (carboplatin and paclitaxel). With treatment, early-stage ovarian cancer has a 5-year overall survival of 70% to 95%. Advanced-stage ovarian cancer may be treated with primary cytoreductive surgery (removal of all visible cancer in the abdominal cavity) and adjuvant chemotherapy (carboplatin and paclitaxel) or with neoadjuvant chemotherapy followed by cytoreductive surgery and adjuvant chemotherapy. Most patients with advanced-stage ovarian cancer receive maintenance therapy with bevacizumab (a monoclonal antibody that blocks angiogenesis) and/or poly–adenosine diphosphate ribose polymerase (PARP) inhibitors. With treatment, the 5-year overall survival rate for advanced-stage ovarian cancer is 10% to 40%. However, individuals with BRCA -related gene variants have a 5-year overall survival rate of approximately 70% with PARP inhibitor treatment. Despite an initial remission rate of 80%, approximately 75% of patients with advanced-stage disease have ovarian cancer relapse within 2 years. Conclusions and Relevance Approximately 21 000 women are diagnosed with ovarian cancer annually in the US, and approximately 80% have advanced-stage ovarian cancer at diagnosis. First-line treatment of early-stage ovarian cancer is surgery and adjuvant platinum-based chemotherapy. Treatment of advanced-stage ovarian cancer includes cytoreductive surgery, platinum-based chemotherapy, and targeted maintenance therapies such as bevacizumab and/or PARP inhibitors.
A reply to the comment on “investigating the ‘diabetes paradox’ in Takotsubo cardiomyopathy”
Chia, Jia Ee , Lee, Kwan , Shanmugasundaram, Madhan , Deshmukh, Abhishek , Krittanawong, Chayakrit , Mukherjee, Debabrata , Lavie, Carl J. , Ang, Song P , Chia, Jia Ee , Lee, Kwan S , Deshmukh, Abhishek J , Krittanawong, Chayakrit , Mukherjee, Debabrata , Lavie, Carl J , Ang, Song Peng , Iglesias, José

Postgraduate Medicine | July 21, 2025 | Volume: 137 | Issue: 7 | Pages: 555-556

10.1080/00325481.2025.2537614 | PMID 40689872 Get It

Commentary: Triple Therapy for NeuroEndovascular Procedures
Frol, Senta , Bendok, Bernard R. , Levy, Elad I.

Operative Neurosurgery | July 21, 2025 | Volume: 29 | Issue: 3 | Pages: 454-455

10.1227/ons.0000000000001730 | PMID 40689627 Get It

Transsellar and Transplanum Endoscopic Endonasal Resection of a Sellar and Suprasellar Craniopharyngioma With Virtual Reality Modeling: 2-Dimensional Operative Video
Olson, Vita A. , Miglani, Amar , Nguyen, Brandon , Spina, Samantha N., Patra, Devi Prasad, Batjer, H. Hunt , Bendok, Bernard R. , Moussalem, Charbel K, Patra, Devi P. , Bendok, Bernard R , Spina, Samantha N., Moussalem, Charbel K.

Operative Neurosurgery | July 21, 2025 | Volume: 30 | Issue: 4 | Pages: 629-630

10.1227/ons.0000000000001720 | PMID 40689644 Get It

The incidence and predictors of false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) in biliary strictures: A prospective study
Aggarwal, Manik , Gores, Gregory J. , Law, Ryan , Martin, John A. , Petersen, Bret T. , Eaton, John E. , Roberts, Lewis R. , Gores, Gregory J. , Vargas, Eric J , Storm, Andrew C , Law, Ryan J, Roberts, Lewis R , Chandrasekhara, Vinay , Aggarwal, Manik , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu , Petersen, Bret T. , Ilyas, Sumera I. , Chandrasekhara, Vinay

Hepatology Communications | July 21, 2025 | Volume: 9 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000751 | PMID 40689505 Get It

Background: Fluorescence in situ hybridization (FISH) is recommended as part of multimodality sampling in the evaluation of biliary strictures, but can be false negative in 40%–50% cases. The aim of this study was to comprehensively assess predictors of false-negative FISH in patients with biliary strictures. Methods: Patients undergoing tissue sampling for biliary strictures from October 20 to February 22 were prospectively enrolled (NCT04572711). Procedural factors such as sampling techniques, order, and utilization of combination sampling were recorded. Results of an optimized pancreatobiliary FISH panel with locus-specific probes for 1q21, 7p12, 8q24, and 9p21 were reported per guidelines. Statistical analyses were performed using BlueSky Statistics v.10.3.1, R package v8.81. Results: Of 327 patients, 93 (28.5%) were diagnosed with malignancy. A false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) was reported in 40 (43.1%) patients. A history of primary sclerosing cholangitis was associated with lower odds of having a false-negative PB-FISH (aOR=0.38, 95% CI=0.16–0.82, p=0.02), whereas a hilar stricture was associated with a significantly higher false-negative PB-FISH in those with cholangiocarcinoma (aOR=3.2 [1.4–7.9], p=0.009). Dilation of biliary strictures prior to brushing was not associated with a lower rate of false-negative PB-FISH. Conclusions: In this prospective study, hilar strictures were more likely to have false-negative PB-FISH. Dilation of strictures did not affect PB-FISH performance. These results can help guide PB-FISH interpretation.
Variant‐Specific Late Gadolinium Enhancement Patterns Influence Clinical Outcomes in LMNA ‐Related Cardiomyopathy
Castrichini, Matteo , Garmany, Ramin , Siontis, Konstantinos C. , Collins, Jeremy D. , Bois, John P. , Pereira, Naveen L. , Tester, David J. , Gluscevic, Martina, Huynh, Trung, Neves, Raquel , Rosenbaum, Andrew , Ackerman, Michael J. , Giudicessi, John R. , Rosenbaum, Andrew N , Collins, Jeremy , Neves, Raquel Almeida Lopes , Castrichini, Matteo , Huynh, Trung , Garmany, Ramin

Journal of the American Heart Association | July 21, 2025 | Volume: 14 | Issue: 15 | Pages: No page available

10.1161/jaha.124.041230 | PMID 40689545 Get It

Background Disease‐causative variants in LMNA ‐encoded lamin A/C cause a genetic cardiomyopathy characterized by atrioventricular block, atrial fibrillation, ventricular arrhythmias, and systolic dysfunction. The influence of LMNA variant type/localization on late gadolinium enhancement (LGE) patterns and clinical outcomes remains unclear. Methods Retrospective analysis of 822 genotype‐positive patients with arrhythmogenic/dilated cardiomyopathy was used to identify those with disease‐causative variants in LMNA . Data on LGE distribution and prevalence of advanced heart failure, thromboembolic and sudden cardiac death/major ventricular arrhythmia events were extracted from the electronic record and analyzed by variant type/localization. Results Among the 72/116 (62%) LMNA variant‐positive patients with cardiac magnetic resonance imaging data, LGE was observed in 40/72 (56%) cases. Most exhibited a nonischemic, midmyocardial or subepicardial pattern (73%), and 6/40 (15%) showed a unique “pseudo‐infarct” transmural pattern, predominantly affecting the apical segments. All 6 patients with this distinct LGE pattern harbored C‐terminal IgD (immunoglobulin‐like domain) variants (p.Arg471His or p.Arg541His). In patients with clinically manifest disease (76/116), those with IgD‐localizing variants had a lower prevalence of atrioventricular block (25% versus 72%, P =0.002) and atrial fibrillation (50% versus 81%, P =0.019) but higher rates of thromboembolic events (42% versus 16%, P =0.038). During a median follow‐up of 37 months, IgD variant presence independently predicted sudden cardiac death/major ventricular arrhythmia (hazard ratio, 2.391 [95% CI, 1.046–5.464]; P =0.039). Conclusions LMNA missense variants localizing to IgD present a distinct apical pseudo‐infarct LGE pattern associated with increased risk of ventricular arrhythmias and thromboembolic events but reduced atrioventricular block and atrial fibrillation. Multicenter studies are warranted to develop variant‐specific risk‐stratification strategies in cardiac laminopathy.
Adult Congenital Heart Disease as a Career? Examining Encouraging and Deterring Factors in the Global ACHD Survey
Bravo‐Jaimes, Katia , Srour, M. , Luna‐López, Raquel , Kandavello, Geetha , Guerrero‐Chalela, Carlos‐Eduardo , García‐Cruz, Edgar , Ackerman, Judith , Elizari, Amalia , Valdez‐Ramos, Miriam , Cupido, Blanche , Almasri, Murad , Phillips, Sabrina D. , Windram, Jonathan , Srour, M H D Osama, Jenkins, Petra , Luna-Lopez, Raquel , Kandavello, Geetha , Guerrero-Chalela, Carlos-Eduardo , García-Cruz, Edgar , Ackerman, Judith , Valdez-Ramos, Miriam , Cupido, Blanche , Zentner, Dominica , Phillips, Sabrina, McLeod, Christopher J , Burchill, Luke J , Kamath, Celia C , Bullock-Palmer, Renee P , Bravo-Jaimes, Katia , Srour, M. H. D. Osama, Tutarel, Oktay , McLeod, Christopher J. , Burchill, Luke J. , Kamath, Celia , Bullock-Palmer, Renée P.

Journal of the American Heart Association | July 21, 2025 | Volume: 14 | Issue: 15 | Pages: No page available

10.1161/jaha.125.041276 | PMID 40689513 Get It

Background There is a global mismatch between the number of adults with congenital heart disease and adult congenital heart disease (ACHD) cardiologists, potentially impacting patient outcomes. This survey explores factors influencing trainees and cardiologists' career choices in ACHD. Methods An online, anonymous global survey on demographics, ACHD as a career choice, encouraging and deterring factors assessed via a 5‐point Likert scale and open‐ended questions on recommending ACHD was distributed through targeted emails and social media. Responses meeting a 75% completion criterion were analyzed using descriptive statistics and thematic analysis. Results Among 811 included responses, most were from women (53.5%), aged 31 to 40 years (48.3%), White individuals (43.3%), non‐Hispanic individuals (85%), from outside the ACHD field (79.0%), and from North America (42.7%). Only 30.9% of non‐ACHD physicians considered specializing in ACHD despite 78.9% recommending it. Encouraging factors included awareness of ACHD significance, mentor influence, and clinical exposure. Key deterrents were inadequate financial incentives, limited job opportunities, and lengthy training. Regional variations showed that longer training duration and lack of compensation incentives were the main deterrents in North America. Suggested solutions included structured training programs, salary improvements, and early ACHD exposure during medical education. Conclusions Less than a third of respondents considered ACHD as a career largely due to inadequate financial incentives, limited job opportunities, and long training duration. Addressing these barriers could enhance recruitment and help meet the growing demands of the ACHD population.